Fabre Hugo, Ducret Maxime, Degoul Olivier, Rodriguez Jonathan, Perrier-Groult Emeline, Aubert-Foucher Elisabeth, Pasdeloup Marielle, Auxenfans Céline, McGuckin Colin, Forraz Nico, Mallein-Gerin Frédéric
Laboratory of Tissue Biology and Therapeutic Engineering, CNRS UMR 5305, University Claude Bernard-Lyon 1 and University of Lyon, 7 Passage du Vercors, 69367 Lyon, France.
CTI-BIOTECH, Cell Therapy Research Institute, 5 Avenue Lionel Terray, 69330 Meyzieu, France.
Stem Cells Int. 2019 Jun 20;2019:2186728. doi: 10.1155/2019/2186728. eCollection 2019.
Mesenchymal stem cells (MSCs) represent alternative candidates to chondrocytes for cartilage engineering. However, it remains difficult to identify the ideal source of MSCs for cartilage repair since conditions supporting chondrogenic induction are diverse among published works. In this study, we characterized and evaluated the chondrogenic potential of MSCs from bone marrow (BM), Wharton's jelly (WJ), dental pulp (DP), and adipose tissue (AT) isolated and cultivated under serum-free conditions. BM-, WJ-, DP-, and AT-MSCs did not differ in terms of viability, clonogenicity, and proliferation. By an extensive polychromatic flow cytometry analysis, we found notable differences in markers of the osteochondrogenic lineage between the 4 MSC sources. We then evaluated their chondrogenic potential in a micromass culture model, and only BM-MSCs showed chondrogenic conversion. This chondrogenic differentiation was specifically ascertained by the production of procollagen IIB, the only type II collagen isoform synthesized by well-differentiated chondrocytes. As a pilot study toward cartilage engineering, we encapsulated BM-MSCs in hydrogel and developed an original method to evaluate their chondrogenic conversion by flow cytometry analysis, after release of the cells from the hydrogel. This allowed the simultaneous quantification of procollagen IIB and 10, a subunit of a type II collagen receptor crucial for proper cartilage development. This work represents the first comparison of detailed immunophenotypic analysis and chondrogenic differentiation potential of human BM-, WJ-, DP-, and AT-MSCs performed under the same serum-free conditions, from their isolation to their induction. Our study, achieved in conditions compliant with clinical applications, highlights that BM-MSCs are good candidates for cartilage engineering.
间充质干细胞(MSCs)是软骨工程中软骨细胞的替代候选细胞。然而,由于已发表研究中支持软骨生成诱导的条件各不相同,因此仍难以确定用于软骨修复的理想MSCs来源。在本研究中,我们对在无血清条件下分离培养的来自骨髓(BM)、脐带华通氏胶(WJ)、牙髓(DP)和脂肪组织(AT)的MSCs的软骨生成潜力进行了表征和评估。BM-MSCs、WJ-MSCs、DP-MSCs和AT-MSCs在活力、克隆形成能力和增殖方面没有差异。通过广泛的多色流式细胞术分析,我们发现这4种MSCs来源在骨软骨生成谱系标志物方面存在显著差异。然后,我们在微团培养模型中评估了它们的软骨生成潜力,只有BM-MSCs表现出软骨生成转化。这种软骨生成分化通过原胶原IIB的产生得到了明确证实,原胶原IIB是分化良好的软骨细胞合成的唯一II型胶原异构体。作为软骨工程的一项初步研究,我们将BM-MSCs封装在水凝胶中,并开发了一种原始方法,在细胞从水凝胶中释放后,通过流式细胞术分析评估它们的软骨生成转化。这使得能够同时定量原胶原IIB和10,10是II型胶原受体的一个亚基,对正常软骨发育至关重要。这项工作代表了在相同无血清条件下,从人BM-MSCs、WJ-MSCs、DP-MSCs和AT-MSCs的分离到诱导,对其详细免疫表型分析和软骨生成分化潜力进行的首次比较。我们在符合临床应用的条件下完成的研究强调,BM-MSCs是软骨工程的良好候选细胞。